Opus Genetics (IRD) Notes Payables (2019 - 2022)
Opus Genetics (IRD) reported Notes Payables of $215000.0 for Q1 2022, down 60.04% on a QoQ basis from $538000.0 in Q4 2021.
Opus Genetics (IRD) has 3 years of Notes Payables data on file, last reported at $215000.0 in Q1 2022.
- Quarterly Notes Payables changed N/A year-over-year to $215000.0 in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $215000.0 (changed N/A YoY) and the FY2021 annual result came in at $538000.0, changed N/A from the prior year.
- Notes Payables eased to $215000.0 in Q1 2022 per IRD's latest filing, from $538000.0 in the prior quarter.
- Across five years, Notes Payables topped out at $5.0 million in Q4 2019 and bottomed at $215000.0 in Q1 2022.
- The 3-year median for Notes Payables is $538000.0 (2021), against an average of $1.9 million.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 215,000.00 |
| Dec 31, 2021 | 538,000.00 |
| Dec 31, 2019 | 4.98 Mn |